Finanzen von Vivos Therapeutics Inc (VVOS)VVOSVivos Therapeutics Inc

Vivos Therapeutics Inc (VVOS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Appliance sales to integrated providers, accounting for 26.9% of total sales, equivalent to $1.03M. Other significant revenue streams include Center revenue and Sleep testing services. Understanding this composition is critical for investors evaluating how VVOS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Vivos Therapeutics Inc maintains a gross margin of 47.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -93.63%, while the net margin is -107.18%. These profitability ratios, combined with a Return on Equity (ROE) of -6629.17%, provide a clear picture of how effectively VVOS converts its operational activities into shareholder value.

In the context of the broader market, VVOS competes directly with industry leaders such as XAIR and BJDX. With a market capitalization of $3.94M, it holds a significant position in the sector. When comparing efficiency, VVOS's gross margin of 47.41% stands against XAIR's 12.73% and BJDX's N/A. Such benchmarking helps identify whether Vivos Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Vivos Therapeutics reported a revenue of $5.2 million in Q2 2026, a 35% increase year-over-year, but still faces a net loss of $5.5 million, highlighting ongoing financial challenges. The gross margin improved to 57%, but the overall financial health remains concerning due to increasing losses.